Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Nestlé to acquire peanut allergy drugmaker for $2.6B

By Sean Whooley | August 31, 2020

Nestlé (VTX:NESN) announced today that it entered into a definitive agreement to acquire food allergy treatment developer Aimmune Therapeutics (NSDQ:AIMT).

Under the agreement, Nestlé Health Science (NHSc) would acquire Aimmune with a cash offer for $34.50 per share, totaling approximately $2.6 billion. The per-share price for Aimmune represents a 174% premium to the company’s closing share price of $12.60 on Aug. 28. Currently, shares of AIMT are trading up 171.6% at $34.22 per share. Nestlé plans to finance the transaction with cash on hand, according to a news release, with the acquisition set to close in the fourth quarter of 2020.

Currently, NHSc has a total investment in Aimmune of $473 million, totaling an approximate 25.6% equity ownership stake. NHSc made its initial investment ($145 million) in the company in November 2016, then invested $30 million in February 2018, $98 million in November 2018 and $200 million in January 2020.

Nestlé said in the release that it expects the acquisition to be accretive to Nestle’s organic growth in 2021 and accretive to cash earnings by 2022/2023.

Aimmune develops Palforzia, the first and only FDA-approved treatment for reducing the frequency and severity of allergic reactions to peanuts, including anaphylaxis, in children ages 4 through 17. Nestlé intends to use the acquisition to extend NHSc’s food allergy portfolio.

“This transaction brings together Nestlé’s nutritional science leadership with one of the most innovative companies in food allergy treatment,” Nestlé Health Science CEO Greg Behar said in the release. “Together we will be able to offer a wide range of solutions that can transform the lives of people suffering from food allergies around the world.”

“The agreement with Nestlé Health Science recognizes the value created by years of commitment and dedication to our mission by the team at Aimmune,” added Aimmune president & CEO Dr. Jayson Dallas. “Delivering Palforzia, the world’s first treatment for food allergy, has been a game-changing proposition in the biopharmaceutical industry and is transformative for the lives of millions of people living with potentially life-threatening peanut allergy.

“This acquisition ensures a level of support for Palforzia and our pipeline that will further enhance their potential for patients around the world living with food allergies.”


Filed Under: Drug Delivery, Drug Discovery, Drug Discovery and Development
Tagged With: Aimmune Therapeutics, Nestle, peanut allergy drug
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50